1.	Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D9901 CDR0000067868, DEN-D9901, NCI-G00-1789, NCT00005947
2.	Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D9902B, UCLA-0307121-01, DEN-D9902B, NCT00065442
3.	Phase II Study of APC8015 (Provenge) and Bevacizumab in Patients With Progressive Prostate Cancer Phase: Phase II Type: Treatment Status: Completed Age: Not specified Sponsor: NCI Protocol IDs: UCSF-0155-01, NCI-2617, UCSF-01554, NCT00027599, 2617
4.	To Evaluate Sipuleucel-T Manufactured With Different Concentrations of PA2024 Antigen Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P07-2, NCT00715078
5.	Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P07-1, NCT00715104
6.	Open Label Study of Sipuleucel-T Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P09-1, NCT00901342
7.	Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P10-2, NCT01431391